Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response-Reference-Cited by-同舟云学术

Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response

Published:2021-10-28 Issue:1 Volume:82 Page:142-154
ISSN:0008-5472
Container-title:Cancer Research
language:en
Short-container-title:Cancer Res

Author:

Kang Hyeon Gu^ORCID,Hwangbo Haeun,Kim Myung Ji,Kim Sinae,Lee Eun Ji,Park Min Ji,Kim Jae-Weon,Kim Byoung-Gie^ORCID,Cho Eun-Hae^ORCID,Chang Suhwan,Lee Jung-Yun^ORCID,Choi Jung Kyoon

Funder

National Research Foundation

Innovation Growth Engine for Planning and Demonstration of the Commercialization Promotion Agency For R&D Outcomes

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. expHRD: an individualized, transcriptome-based prediction model for homologous recombination deficiency assessment in cancer;BMC Bioinformatics;2024-07-12

2. RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer;Frontiers in Oncology;2024-04-25

3. Homologous Recombination Deficiency Detection Algorithms: A Systematic Review;Cancers;2023-11-29

4. RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men With Prostate Cancer;JCO Precision Oncology;2023-09

5. Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045;International Journal of Cancer;2023-08-21